Skip to main content
ATOSSA THERAPEUTICS, INC. logo

ATOSSA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · ATOS ISIN · US04962H5063 US Manufacturing
Open in API
Filings indexed 622 across all filing types
Latest filing 2014-06-26 Regulatory Filings
Country US United States of America
Listing US ATOS

About ATOSSA THERAPEUTICS, INC.

https://atossatherapeutics.com/

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative medicines for areas of significant unmet medical need, with a primary focus on oncology. The company is dedicated to addressing the full continuum of breast cancer care. Its lead program is centered on (Z)-endoxifen, a proprietary and potent selective estrogen receptor modulator (SERM). Atossa is advancing (Z)-endoxifen through clinical development for multiple breast cancer indications, including metastatic disease, aiming to provide a therapeutic with a potentially improved efficacy and tolerability profile.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated June 24, 2014, reporting a change in the company's independent registered public accounting firm. It details the dismissal of the previous auditor and the engagement of a new auditor, including references to audit reports and letters from the former auditor. There are no financial statements or substantive financial data included, only disclosures about auditor changes and related correspondence. This type of filing is specifically about audit firm changes and does not constitute a full audit report or annual report. Therefore, it fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous filings that do not fit other categories and includes auditor change announcements.
2014-06-26 English
PRIMARY DOCUMENT
Director's Dealing
2014-06-06 English
8-A12B
Regulatory Filings Classification · 100% confidence The document is a Form 8-A filed with the SEC, which is used for the registration of certain classes of securities pursuant to Section 12(b) or 12(g) of the Securities Exchange Act of 1934. The text details the terms of a rights distribution related to the company's common stock, including descriptions of rights issuance, distribution dates, redemption, and other related provisions. This is a regulatory filing related to securities registration and rights offering, not a financial report, earnings release, or management discussion. It does not contain financial statements or earnings data, nor is it an announcement of voting results or management changes. The document is a formal regulatory filing required by the SEC to register securities and disclose rights terms. Therefore, the appropriate classification is Regulatory Filings (RNS).
2014-05-22 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the declaration of a dividend distribution of rights, details of a Rights Agreement, and terms related to the issuance, exercise, and redemption of these rights. This is a material definitive agreement disclosure, which is a typical use of Form 8-K to announce significant corporate actions or agreements. It is not an annual or quarterly report, earnings release, or management discussion. It is not a proxy statement or voting results announcement. The document is a regulatory filing announcing a material event, specifically the entry into a material definitive agreement (the Rights Agreement). Therefore, the appropriate classification is Regulatory Filings (RNS). The document length and detail confirm it is not a brief announcement but a full disclosure under Form 8-K, which fits the RNS category best as per the definitions and rules provided.
2014-05-22 English
FORM 10-Q
Interim / Quarterly Report Q1 2014
2014-05-14 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 14, 2014, by Atossa Genetics Inc. It announces the issuance of a press release regarding first quarter 2014 financial results. The document itself is short (3110 characters) and primarily serves to report the release of financial results via a press release attached as Exhibit 99.1. There are no detailed financial statements or substantive financial data within this document; it is an announcement of the earnings release rather than the earnings release itself. According to the classification rules, such a document is best classified as an Earnings Release (ER) because it announces quarterly financial results, but since the actual detailed financial data is in the attached press release, and the 8-K is the official filing of that announcement, the best fit is ER. The document is not a full quarterly report (IR), nor is it a report publication announcement (RPA) because it includes the press release as an exhibit and is the official filing of the earnings announcement. Therefore, the classification is ER with high confidence.
2014-05-14 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.